title: Dendritic cell-based vaccine for the treatment of malignant glioma: a systematic review.
abstract: OBJECTIVE
  Glioblastoma multiforme (GBM) has a poor prognosis. The purpose of this systematic review and meta-analysis was to analyze the outcomes of clinical trials which compared immunotherapy with conventional therapy for the treatment of malignant gliomas.
  
  
  METHODS
  PubMed, Cochrane and Google Scholar databases were searched for relevant studies. The 2-year survival rate was used to evaluate effectiveness of immunotherapy.
  
  
  RESULTS
  Of 171 studies identified, six comparative trials were included in the systematic review. Immunotherapy was associated with a significantly longer OS and 2-year survival compared to conventional therapy.
  
  
  CONCLUSIONS
  Immunotherapy may improve the survival of patients with GBM.
authors.affiliation: Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Wang
authors.forename: Hong-Yang
authors.initials: HY
authors.lastname: Zhao
authors.forename: Fang-Cheng
authors.initials: FC
authors.lastname: Zhang
authors.forename: Yun
authors.initials: Y
authors.lastname: Sun
authors.forename: Zhi-Yong
authors.initials: ZY
authors.lastname: Xiong
authors.forename: Xiao-Bing
authors.initials: XB
authors.lastname: Jiang
mesh_terms: D001932:Brain Neoplasms / Q000276:immunology / Q000628:therapy*; D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology*; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D019496:Cancer Vaccines
keywords: Dendritic cell vaccination; Glioblastoma multiforme; Immunotherapy; Survival